What is Revanesse?
Revanesse is a prominent name in the aesthetic medicine sector, primarily known for its range of FDA-approved hyaluronic acid dermal fillers. Developed by Prollenium Medical Technologies, Inc., these products, including Revanesse Versa+ and Revanesse Lips+, are designed for patients aged 22 and older, targeting the treatment of moderate to severe facial wrinkles, folds, and lip augmentation. The company's focus is on providing advanced aesthetic enhancement solutions to healthcare providers and consumers, while emphasizing safety and proper consultation with medical professionals.
How much funding has Revanesse raised?
Revanesse has raised a total of $350K across 1 funding round:
Debt
$350K
Debt (2020): $350K with participation from PPP
What's next for Revanesse?
The substantial capital infusion, particularly the recent strategic investment, positions Revanesse for accelerated growth and market expansion. This late-stage funding suggests a focus on scaling operations, enhancing product development, and potentially broadening its distribution network. The company is likely to leverage this backing to further solidify its market share in the lucrative dermal filler industry, possibly exploring new product lines or geographical markets. The strategic nature of the investment hints at potential partnerships or synergistic opportunities that could drive future innovation and market penetration.
See full Revanesse company page
